Pharmaceutical Composition for the Diagnosis or Treatment of Plasmacytoma

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to pharmaceutical and diagnostic compositions containing nucleic acid aptamers that specifically bind to myeloma (multiple myeloma) IgG antibodies. The invention enables both the early diagnosis of multiple myeloma, a malignant plasma cell cancer, and the therapeutic removal or neutralization of pathogenic myeloma antibodies from patient blood. These nucleic acid aptamers exhibit high specificity for myeloma-specific IgG, distinguishing them from normal antibodies, and can be used in diagnostic kits, therapies, and specialized dialysis devices.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and sensitive diagnostic detection of multiple myeloma via blood or plasma assays using the nucleic acid aptamers as detection reagents.
• Therapeutic removal of harmful myeloma IgG antibodies from patient blood, either via pharmaceutical administration or with specialized dialysis devices.
• Enabling ex-vivo diagnostic tests for clinical laboratories for myeloma disease monitoring and minimal residual disease detection.
• Development of biosensor devices or point-of-care diagnostic kits for rapid detection of myeloma antibodies in patients.
• Adjunct therapy for myeloma patients to reduce antibody-induced organ damage, especially in combination with traditional chemotherapy or immunomodulatory treatment.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific binding to myeloma IgG antibodies enables precise diagnosis with reduced risk of false positives or negatives.
• Early detection allows for earlier intervention, potentially improving patient prognosis and survival rates.
• Aptamer-based therapy removes pathogenic antibodies, which may reduce or prevent organ and tissue damage often seen in myeloma patients, improving quality of life.
• Compositions do not significantly disturb normal immune responses, preserving the body's natural defense against other antigens.
• Aptamers can be produced synthetically, allowing for scalability and batch consistency compared to traditional antibody production.
• Aptamers can be used in diverse formats (pharmaceuticals, diagnostics, immobilized on surfaces, coupled to markers), making them versatile tools in both treatment and clinical testing.
• Diagnostic kits and devices based on this technology can be made for point-of-care or laboratory settings, enhancing healthcare accessibility and workflow.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to pharmaceutical or diagnostic compositions which contain nucleic acids that bond to myeloma antibodies.